PAI
Palo Alto Investors Portfolio holdings
AUM
$470M
1-Year Return
2.57%
This Quarter Return
+2.67%
1 Year Return
+2.57%
3 Year Return
+93.77%
5 Year Return
+190.64%
10 Year Return
+955.02%
AUM
$770M
AUM Growth
-$93.1M
(-11%)
Cap. Flow
-$82.4M
Cap. Flow
% of AUM
-10.7%
Top 10 Holdings %
Top 10 Hldgs %
76.77%
Holding
47
New
8
Increased
7
Reduced
11
Closed
2
Top Buys
| 1 |
Alnylam Pharmaceuticals
ALNY
|
+$38.7M |
| 2 |
PTC Therapeutics
PTCT
|
+$9.81M |
| 3 |
Iovance Biotherapeutics
IOVA
|
+$8.69M |
| 4 |
BioNTech
BNTX
|
+$2.99M |
| 5 |
Edwards Lifesciences
EW
|
+$2.6M |
Top Sells
| 1 |
United Therapeutics
UTHR
|
+$30M |
| 2 |
RVNC
Revance Therapeutics, Inc.
RVNC
|
+$18.9M |
| 3 |
Insmed
INSM
|
+$14.5M |
| 4 |
Biogen
BIIB
|
+$11.7M |
| 5 |
STAAR Surgical
STAA
|
+$10.8M |
Sector Composition
| 1 | Healthcare | 98.76% |
| 2 | Financials | 1.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
VERV
26
DELISTED
Verve Therapeutics
VERV
| $2.79M | 0.36% |
575,817
| – | – |
|
|
27
Edwards Lifesciences
EW
$45.5B
| $2.6M | 0.34% |
+39,473
| New | +$2.6M |
|
28
Mirum Pharmaceuticals
MIRM
$3.73B
| $2.52M | 0.33% |
64,700
| – | – |
|
29
Relmada Therapeutics
RLMD
$52.8M
| $2.37M | 0.31% |
732,400
| – | – |
|
30
Nuvation Bio
NUVB
$1.07B
| $1.77M | 0.23% |
772,652
| – | – |
|
31
Taysha Gene Therapies
TSHA
$837M
| $1.63M | 0.21% |
811,268
| – | – |
|
32
Travere Therapeutics
TVTX
$2.09B
| $1.55M | 0.2% |
110,719
| – | – |
|
33
Stoke Therapeutics
STOK
$1.29B
| $1.55M | 0.2% |
125,861
| – | – |
|
|
BCYC
34
Bicycle Therapeutics
BCYC
$490M
| $1.35M | 0.18% |
+59,582
| New | +$1.35M |
|
35
Humana
HUM
$33.2B
| $1.26M | 0.16% |
3,985
| – | – |
|
36
Aldeyra Therapeutics
ALDX
$324M
| $1.22M | 0.16% |
225,465
| – | – |
|
37
VYNE Therapeutics
VYNE
$7.91M
| $837K | 0.11% |
445,434
| – | – |
|
|
ELEV
38
DELISTED
Elevation Oncology
ELEV
| $779K | 0.1% |
1,298,097
-502,009
| -28% | -$301K |
|
39
Instil Bio
TIL
$163M
| $752K | 0.1% |
+11,165
| New | +$752K |
|
40
Aclaris Therapeutics
ACRS
$211M
| $655K | 0.09% |
569,832
| – | – |
|
41
Pyxis Oncology
PYXS
$113M
| $624K | 0.08% |
+170,000
| New | +$624K |
|
42
Generation Bio
GBIO
$39.9M
| $372K | 0.05% |
15,048
| – | – |
|
|
BLUE
43
DELISTED
bluebird bio
BLUE
| $314K | 0.04% |
30,213
-201,455
| -87% | -$2.09M |
|
44
UroGen Pharma
URGN
$869M
| $311K | 0.04% |
24,500
| – | – |
|
45
Abeona Therapeutics
ABEO
$330M
| $81.3K | 0.01% |
+12,865
| New | +$81.3K |
|
46
Cytokinetics
CYTK
$6.12B
| – | – |
-111,717
| Closed | -$6.05M |
|